The startup's asthma solution, called Mya, combines home-based diagnostics, digital health and a care team to identify patients at risk and proactively intervene to prevent asthma attacks.
The companies in the track span therapeutic drug monitoring to enhance efficacy, personal nutrition, assessing traumatic brain injury and more.
In a recent interview, Esperion president and CEO, Sheldon Koenig talks about the reality of statin intolerance and his company’s expansion into new diseases
Among the finalists for the chronic disease management and value-based care track are a virtual care business serving the needs of patients with neurological disorders and their family caregivers, digital therapeutics for adolescent mental health, and personalized nutrition coaching to address chronic disease risk.